BCG Vaccination, COVID-19
Conditions
Keywords
Outcome, COVID-19 pneumonia, BCG, Tuberculin test positive, Egypt
Brief summary
There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown
Interventions
DIAGNOSTIC_TESTTuberculin test
Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
Sponsors
Assiut University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* COVID-19 positive cases admitted to hospitals in Upper Egypt
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pneumonia severity index | 2 weeks | severity of COVID-19 pneumonia |
| Need for ICU admission | 2 weeks | severe pneumonia indicating invasive or non invasive mechanical ventilation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| COVID -19 test conversion | 2 weeks | number of days to cure from COVID-19 disease |
| Mortality | 2 weeks | frequency of fatalities |
Countries
Egypt
Outcome results
None listed